Research And Development
Health
Manufacturing

Immunomedics

$18.00
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.08 (0.46%) Today
+$0.42 (2.39%) After Hours

Why Robinhood?

You can buy or sell Immunomedics and other stocks, options, ETFs, and crypto commission-free!

About

Immunomedics, Inc. Common Stock, also called Immunomedics, is a clinical-stage biopharmaceutical company, which engages in the business of researching, developing, manufacturing and marketing biopharmaceutical products. Read More It focuses on monoclonal antibody-based products for the targeted treatment of cancer. It operates through the United States, and Europe geographical segments. The company was founded by David M. Goldenberg in July 1982 and is headquartered in Morris Plains, NJ.

Employees
185
Headquarters
Morris Plains, New Jersey
Founded
1982
Market Cap
3.27B
Price-Earnings Ratio
Dividend Yield
Average Volume
2.46M
High Today
$17.68
Low Today
$16.96
Open Price
$17.46
Volume
993.77K
52 Week High
$27.33
52 Week Low
$11.55

Collections

Research And Development
Health
Manufacturing
Cancer Prevention
Pharmaceutical
Biopharmaceutical
Medical
Biotechnology

News

MarketBeatMar 4

Stock Price, News, & Analysis for Immunomedics

Immunomedics, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer. Its advanced antibody-drug conjugates are sacituzumab govitecan and labetuzumab govitecan, which are in advanced trials for various solid tumors and metastatic colorectal cancer, respectively. The company focuses on commercializing sacituzumab govitecan as a third-line therapy for patients with metastatic triple-negative breast cancer in the United States. The com...

100
Yahoo FinanceFeb 26

The Daily Biotech Pulse: Immunomedics CEO Departs, Ultragenyx Offering, Karyopharm Awaits FDA Panel Vote

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks Scroll to continue with content Ad (Biotech stocks hitting 52-week highs on Feb. 25) Abbott Laboratories (NYSE: ABT) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) Argenx SE – ADR (NASDAQ: ARGX) Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN) Clementia Pharmaceuticals Inc (NASDAQ: CMTA)( announced a deal to be acquired by IPSEN S A/S ADR (OTC: IPSEY) Eton Pharmaceuticals Inc (NASDAQ: ETON) Gossamer ...

299
Seeking AlphaFeb 25

Immunomedics CEO exits; shares down 11%

Alongside Q4 results, Immunomedics (NASDAQ:IMMU) announces the exit of President and CEO Michael Pehl, due to personal reasons. Dr. Behzad Aghazadeh has been named Executive Chairman, and Dr. Charles Baum - currently president and CEO of Mirati Therapeutics - has joined the board. Previously: Immunomedics reports 2H results (Feb. 25) IMMU -11.1% after hours Conference call is just underway....

557

Earnings

-$0.68
-$0.46
-$0.24
-$0.02
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Estimated
Actual
Expected May 8, After Hours

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.